Watson’s Bupropion XL Undone By Outlier Patient, Bankrupt CRO
After long delay, FDA quietly reveals second Wellbutrin generic deemed not therapeutically equivalent; ex-Office of Generic Drugs official predicts FDA will tighten criteria for extrapolating data to higher generic strengths.
You may also be interested in...
Mallinckrodt and Kremers seem prepared to fight formal notice, which comes almost two years after FDA found their methylphenidate generics failed to demonstrate bioequivalence to the Janssen's brand drug.
Data integrity spotlight expands beyond cGMP as FDA finds Semler manipulated study subject samples in bioequivalence studies conducted at its Bangalore facility.
Draft guidance provides roadmap for testing generic solid oral opioid products; FDA's Califf notes difficulty in conducting post-market studies.